Skip Navigation


Annals of Oncology Advance Access originally published online on August 5, 2008
Annals of Oncology 2008 19(10):1811-1812; doi:10.1093/annonc/mdn547
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/10/1811    most recent
mdn547v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cazzaniga, M. E.
Right arrow Articles by Floriani, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cazzaniga, M. E.
Right arrow Articles by Floriani, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study

The first 10% of the full text of this article appears below.

Recent data seem to indicate that only some groups of early breast cancer patients benefit from an adjuvant treatment with anthracyclines [1]. In particular, in HER2-positive disease, anthracyclines are reported to be superior to nonanthracycline regimens in terms of disease-free survival (DFS) and overall survival, independently of the method by which the overexpression or amplification was determined.

Few data are available at the moment about a possible benefit of anthracyclines . . . [Full Text of this Article]

M. E. Cazzaniga1,*, P. Pronzato2, G. Mustacchi3, A. De Matteis4, F. Di Costanzo5, E. Rulli6 and I. Floriani6

1 Department of Medical Oncology, San Gerardo Hospital, Monza
2 Department of Medical Oncology, IST, Genoa
3 Department of Medical Oncology, University of Trieste, Trieste
4 Department of Medical Oncology C, Istituto Pascale, Naples
5 Department of Medical Oncology, Ospedale Careggi, Florence
6 Department of Oncology, Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy

* (E-mail: oncologia@tin.it)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?